CD8A and cancer: Although replicating artPICV and artLCMV vectors have not been evaluated for use in HIV, early ongoing clinical trials with these vectors in individuals with recurrent or metastatic HPV16+ cancers have shown good safety and immunogenicity, with frequencies of circulating HPV16 E6/E7-specific CD8+ T cells of up to 40% of the total CD8+ T cells in peripheral blood20.